Vtorichnaya profilaktika ishemicheskogo insul'ta u bol'nykh pozhilogo vozrasta (antiagregantnaya terapiya)
- Authors: Kamchatnov P.R1, Chugunov A.V1, Umarova K.Y.1
-
Affiliations:
- ГОУ ВПО РГМУ, Москва
- Issue: Vol 9, No 12 (2007)
- Pages: 63-68
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/92526
- ID: 92526
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
P. R Kamchatnov
ГОУ ВПО РГМУ, МоскваКафедра неврологии и нейрохирургии лечебного факультета
A. V Chugunov
ГОУ ВПО РГМУ, МоскваКафедра неврологии и нейрохирургии лечебного факультета
Kh. Ya Umarova
ГОУ ВПО РГМУ, МоскваКафедра неврологии и нейрохирургии лечебного факультета
References
- Гусев Е.И., Скворцова В.И. Ишемия головно го мозга. М.: Медицина, 2001.
- Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн. неврол. и психиатр. Прил. Инсульт. 2003; 8: 4–9.
- Гусева О.И., Квасова О.В., Пряникова Н.А. и др. Сравнительный анализ действия дипиридамола и комплекса дипиридамол + аспирин при вторичной профилактике инсуль та. Журн. неврол. и психиатр. Прил. Ин сульт. 2001; 1: 66–71.
- Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Consilium Medicum. Артер. гипертенз. 2004; 10 (3): 54–61.
- Скворцова В.И., Чазова И.Е., Стаховская Л.В. Вторичная профилактика инсульта. М.: ПАГРИ, 2002.
- Aguilar M, Hart R. Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No Previous History of Stroke or Transient Ischemic Attacks. Stroke 2006; 37: 274–5.
- Algra A, van Gijn J. Cumulative meta - analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66: 255–61.
- Antiplatelet Trialists' Collaboration. Collabora tive overview of randomised trials antiplatelet therapy: Prevention of death, myocardial infarc tion, and stroke by prolonged antiplatelet thera py in various categories of patients. BMJ 1994;308: 98–106.
- Arboix A, Miguel M, C?scar E et al. Cardiovas cular risk factors in patients aged 85 or older with ischemic stroke. Clin Neurol Neurosurg 2006; 108 (7): 638–43.
- Ariesen M, Algra A, Kappelle L. Antiplatelet Drugs In the Secondary Prevention After Stroke Differential Efficacy in Large Versus Small Vessel Disease? A Subgroup Analysis From ESPS-2. Stroke 2006; 37: 134–8.
- Berrouschot J, Schwetlick B, von Twickel G et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 113 (1): 31–5.
- Bhatt D, Fox K, Hacke W et al. Clopidogrel and aspirin alone versus aspirin alone for the prevention of atheromathosous effects. N Eng J Med 2005; 354.
- Bhatt D, Flather M, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49 (19): 1982–8.
- Campbell C, Smyth S, Montalescot G et al. Aspirin Dose for the Prevention of Cardiovascu lar Disease. A Systematic Review. JAMA 2007; 297: 2018–24.
- CAPRIE Steering Committee. A randomised blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1333–8.
- Chutka D, Takahashi P, Hoel R. Inappropri ate medications for elderly patients. Mayo Clin Proc 2004; 79 (1): 122–39.
- Collet J, Himbert D, Steg P. Myocardial infarc tion after aspirin cessation in withdrawal. Inter national. J Cardiol 2000; 76: 257–8.
- Coull A, Lovett J, Rothwell P. Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organization of services. BMJ 2004; 328: 326–8.
- De Schryver E, van Gijn J, Kappelle L et al. Non - adherence to aspirin or oral anticoagu lants in secondary prevention after ischaemic stroke. J Neurol 2005; 252 (11): 1316–21.
- De Schryver E, Algra A, van Gijn J. Dipyri damole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006; 2: CD001820.
- Dickerson L, Carek P., Quattlebaum R. Pre vention of recurrent ischemic stroke. Am Fam Physician 2007; 76 (3): 382–8.
- Diener H, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Nerol Sci 1996; 143: 5–13.
- Diener H, Bogousslavsky J, Brass L et al. on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high - risk patients (MATCH): randomised, double - blind, placebo - controlled trial. Lancet. 2004; 364: 331–7.
- Diener H. The PRoFESS trial: future impact on secondary stroke prevention. Expert Rev Neurother 2007; 7 (9): 1085–91.
- Felmeden D, Lip G. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Human Hypertension 2005; 19: 185–96.
- Gent M, Easton Y, Hachinski V et. al. The Canadian American Ticlopidine Study (CATS) in Tromboembolic stroke. Lancet 1989; 1 (8649): 1215–20.
- Gorelick P. Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implica tions for Therapy. Stroke 2002; 33: 862–5.
- Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: popu lation based case - control study. BMJ 2006; 333 (7571): 726–31.
- Hamann G, Weimar C, Glahn J et al. Adher ence to secondary stroke prevention strategies - results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15 (4): 282–8.
- Hankey G.J. Secondary Prevention of Recur rent Stroke. Stroke 2005; 36: 218–23.
- Harbisoa Y. Ticlopidiae versus aspirin for the prevention of recurrent stroke. Stroke 1992; 23 (12): 1723–7.
- Jones L, Griffin S, Palmer S et al. Clinical effec tiveness and cost - effectiveness of clopidogrel and modified - release dipyridamole in the secondary prevention of occlusive vascular events: a sys tematic review and economic evaluation. Health Technol Assess 2004; 8 (38): 1–196.
- Keller T, Squizzato A, Middeldorp S. Clopido grel plus aspirin versus aspirin alone for pre venting cardiovascular disease. Cochrane Data base Syst Rev 2007; 3: CD005158.
- Landi F, Cesari M, Onder G еt al. Antithrombotic drugs in secondary stroke prevention among a community dwelling older population. J Neurol Neurosurg Psychiatry 2003; 74 (8): 1100–4.
- Ling G, Ling S. Preventing ischemic stroke in the older adult. Cleve Clin J Med 2005; 72 (Suppl. 3): S14–25.
- Lip G, Kamath S, Hart R. ABC of antithrom botic therapy: Antithrombotic therapy for cere brovascular disorders. BMJ 2002; 325: 1161–3.
- Lovett J, Coull A, Rothwell P. Early risk of recurrence by subtype of ischemic stroke in population - based incidence studies. Neurology 2004; 62: 569–73.
- Mateen F, Shuaib A. Progress in clinical neu rosciences: The 'antiplatelet' agents and the role of the endothelium. Can J Neurol Sci 2007; 34 (3): 270–9.
- Maulaz A, Bezerra D, Michel P, Bogous slavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62 (8): 1217–20.
- Michelson A, Cattaneo M, Eikelboom J еt al. Aspirin Resistance: Position Paper of the Work ing Group on Aspirin Resistance, Platelet Physi ology Subcommittee of the Scientific and Stan dardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2005; 3: 1–3.
- Morton J, Newton J, Gray C. Counting the true cost of antiplatelet therapy for stroke prevention. Age and Ageing 2005; 34: 212–4.
- Olindo S, Cabre P, Deschamps R еt al. Acute Stroke in the Very Elderly. Epidemiological Fea tures, Stroke Subtypes, Management, and Out - come in Martinique, French West Indies. Stroke 2003; 34: 1593.
- Pulcinelli F, Pignatelli P, Celestini A et al. Inhi bition of platelet aggregation by aspirin progres sively decreases in long - term treated patients. J Am Col Cardiol 2006; 43 (6): 979–84.
- Rojas J, Zurr? M, Romano M et al. Acute ischemic stroke and transient ischemic attack in the very old--risk factor profile and stroke sub type between patients older than 80 years and patients aged less than 80 years. Eur J Neurol 2007; 14 (8): 895–9.
- Sacco R.L, Foulkes M.A, Mohr J et al. Determi nants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989; 20: 983–9.
- Saxena R, Koudstaal P. Anticoagulants for Preventing Stroke in Patients With Nonrheumat ic Atrial Fibrillation and a History of Stroke or Transient Ischemic Attack. Stroke 2004; 35: 1782–3.
- Serebruany V, Malinin A, Ziai W et al. Dipyri damole decreases protease - activated receptor and annexin - vbinding on platelets of post stroke patients with aspirin nonresponsiveness. Cerebrovasc Dis 2006; 21 (1–2): 98–105.
- Sztriha L, Sas K, Vecsei L. Aspirin resistance in stroke: Nerol Sci 2004; 229–30: 163–9.
- The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-Segment elevation. N Engl J Med 2001; 345: 494–502.
- Vermeer S.E, Hollander M, Van Dijk E et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study Stroke 2003; 34: 1126–9.
- Wang T, Bhatt D, Fox K et al. An analysis of mortality rates with dual - antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007; 28 (18): 2200–7.
- Watson R, Chin B, Lip G. ABC of antithrom botic therapy: Antithrombotic therapy in acute coronary syndromes. BMJ 2002; 325: 1348–51.
- Willmot M, Zhao L, Heptinstall S, Bath P. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis 2004; 13 (3): 138–40.
Supplementary files
